




Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Application Number	10/650,434
		Filing Date	August 28, 2003
		First Name Inventor	Binggeli
		Group Art Unit	
		Examiner Name	
Sheet <u>12</u>	Of 2	Attorney Docket Number	21377 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
ATP ↑	C1	Keller and Wahli: Trends Endocrin. Metab. (1993); 4:291-296	
	C2	MacDougald and Lane: Current Biology Vol. 5 pp. 618-621 (1995)	
	C3	Guerre-Millo, et. al.; J Biol Chem 2000; 275: 16638-16642	
	C4	Balfour, et. al.; Drugs 57 (1999) 921-930	
	C5	Haigh et. al., Tetrahedron: Asymmetry, 10, pp. 1353-1367	
	C6	Gotteland et al., Synlett, 9 pp. 931-932 (1995)	
	C7	Hulin et al., J. Med. Chem., 39, pp. 3897-3907 (1996)	
	C8	Nicolaou et al., J. Am. Chem. Soc., 122, pp. 3830-3838 (2000)	
	C9	Nichols et al., Anal. Biochem., 257, pp. 112-119 (1998)	
	C10	Einsiedel et. al., Bioorg. Med. Chem. Lett., 10, pp. 2041-2044 (2000)	
	C11	Goto et al., Chem. Pharm. Bull., 19, pp. 2050-2057 (1971)	
	C12	Reichstein et al., Helvetica Chimica Acta, 16, pp. 121-129 (1933)	
	C13	Diels et al., chem.. Ber., 48, pp. 897-905 (1915)	
	C14	Wightman et al., J. Org. chem., 43, pp. 2167-2170 (1978)	
	C15	Musser et al., J. Med. Chem. 30, pp. 62-67 (1987)	
	C16	Rahman et al., J. Chem. Soc. Perkin Trans. 1, 12, pp. 2973-2977 (1983)	
	C17	Kelly et. al., J. Am. Chem. Soc., 110, pp. 6471-6480 (1988)	
	C18	Kneen et al., Synthetic Communications, 16, pp. 1635-1640 (1986)	
	C19	Kim et al., Can. J. Chem., 60, pp. 2093-2098 (1982)	
	C20	Parkanyi et al., Monatsh. Chem., 123, pp. 637-645 (1992)	
	C21	STN International @ CAPLUS Database, Accession No. 2000; 117035; Collins et al., WO 2000008002, abstract	
	C22	Malamas, MS et al, Eur. J. Med. Chem. Vol. 36, No. 1 (2001) pp. 31-42	
	C23	Hulin, B. et al., Current Pharmaceutical Design, Vol.2 (1996) pp. 85-102	
ATP ↓	C24	Oplinger, et. al., ACS National Meeting, San Diego, April 1-5, 2001, Poster 238, Division of Medicinal Chemistry, Section C	
Examiner Signature	<i>Fiona T. Powers</i>		DATE CONSIDERED <u>4/30/04</u>

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
²Unique citation designation number. ³Applicant is to place a check mark here if English language Translation or abstract is attached.



Substitute for form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number			
(Use several sheets if necessary)				Filing Date			
				First Name Inventor			
				Group Art Unit			
				Examiner Name			
Sheet 1 of 2				Attorney Docket Number			
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
FTP ↑ ↓ FTP	A1	5,856,529		Bristol-Myers Squibb Company <i>Catt et al.</i>	01/05/1999		
	A2	6,121,397		Xerox Corporation <i>Macloed et al.</i>	09/19/2000		
	A3	5,089,514		Bernard Hulin	02/18/1992		
	A4	4,011,326		Jensen	03/08/1977		
	A5	6,291,685		Junghans, et. al.	09/18/2001		
	A6	6,441,185		Kühnle, et. al.	08/27/2002		
	A7	5,599,826		Mertens, et. al.	02/04/1997		
FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ³
		Office ⁴	Number ⁴	Kind Code ⁵ (if known)			
FTP ↑ ↓ FTP	B1	EP	1 078 923		F. Hoffmann-La Roche A.G.	02/28/2001	
	B2	WO	99/10339		Pfizer Products Inc.	03/04/1999	
	B3	WO	02 16331		Eli Lilly & Company	02/28/2002	
	B4	WO	00 08002		Glaxo Group Limited	02/17/2000	X
	B5	WO	91/19702		Pfizer Inc.	12/26/1991	
	B6	WO	94/01420		Smithkline Beecham PLC.	01/20/1994	
	B7	WO	94/13650		Smithkline Beecham PLC.	06/23/1994	
	B8	WO	95/17394		Smithkline Beecham PLC	06/29/1995	
	B9	WO	97/25042		Smithkline Beecham PLC	07/17/1997	
	B10	WO	99/08501		Dr. Reddy's Research Foundation	02/25/1999	
FTP	B11	EP	0903343		SSP Co., Ltd.	03/24/1999	
Examiner Signature	↑	Date Considered			4/30/04		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

From T. Powers